ACM
SLN

ADAR1 Capital Management’s Silence Therapeutics SLN Stock Holding History

ADAR1 Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$907K Buy
172,157
+148,514
+628% +$818K 0.05% 168
2025
Q4 		$144K Buy
23,643
+5,000
+27% +$32K 0.01% 238
2025
Q3 		$96.8K Hold
18,643
– – 0.01% 202
2025
Q2 		$108K Hold
18,643
– – 0.02% 172
2025
Q1 		$52.6K Buy
18,643
+643
+4% +$3.14K 0.01% 180
2024
Q4 		$124K Sell
18,000
-22,290
-55% -$288K 0.02% 174
2024
Q3 		$732K Hold
40,290
– – 0.12% 96
2024
Q2 		$766K Buy
40,290
+200
+0.5% +$4.25K 0.14% 78
2024
Q1 		$866K Buy
40,090
+39,900
+21,000% +$867K 0.2% 63
2023
Q4 		$3.3K Buy
+190
New +$2.13K ﹤0.01% 153

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

ADAR1 Capital Management's SLN Position: Q1 2026 in Review

ADAR1 Capital Management increased its Silence Therapeutics (SLN) stake by 628% in Q1 2026, buying an estimated $818K and bringing the position to 172,157 shares worth $907K. The position accounts for 0.05% of the portfolio, ranked #168.

ADAR1 Capital Management first reported a position in SLN in Q4 2023 and has held it in 10 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • ADAR1 Capital Management held 172,157 shares of Silence Therapeutics worth $907K as of Q1 2026.
  • ADAR1 Capital Management bought 148,514 Silence Therapeutics shares in Q1 2026, an estimated $818K.
  • Silence Therapeutics made up 0.05% of ADAR1 Capital Management's portfolio in Q1 2026, its #168 holding.
  • ADAR1 Capital Management first reported a position in Silence Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.